Poster

A novel mathematical framework to predict in vivo bispecific GTX-B001 binding in skin, and translation to humans

See how quantitative pharmacology and PBPK modeling supported first in human dose selection for a…

Certara2026 年 7 月 20 日

Publication

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data

QSP modeling reveals patient-specific factors driving CAR T-cell response and relapse in multiple myeloma, with…

Certara2026 年 7 月 20 日

On-Demand Webinar

Expert Q&A: Identify Winning Biotherapeutics in Early Discovery

Watch this on-demand Q&A on using mechanistic modeling to assess feasibility and prioritize biotherapeutic candidates…

Certara2026 年 7 月 17 日

Webinar

Integrated mechanistic modeling approaches in oncology drug development

Certara2026 年 7 月 8 日

Poster

将内源性配体竞争纳入治疗性单克隆抗体的机制全身 PBPK 模型

Discover how endogenous ligand competition was incorporated into a whole-body PBPK model to improve prediction…

Certara2026 年 6 月 23 日

Poster

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Learn how Certara's IO Simulator was used to predict efficacy, cytokine release syndrome risk, and…

Certara2026 年 6 月 23 日

Publication

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

See how a QSP model guided efficacy-proximal FIH dosing for ISB 2001 in the TRIgnite-1…

Certara2026 年 6 月 4 日

Video

Applying AI-Driven Biosimulation to Drug Discovery

Certara President Leif Pedersen explains how PBPK and QSP modeling, proven across 125+ FDA-approved drugs,…

Certara2026 年 6 月 2 日

Publication

Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment

This review explores how artificial intelligence (AI), machine learning (ML), and quantitative systems pharmacology (QSP)…

Certara2026 年 6 月 2 日

Blog

ADC Dose Optimization: Applying Model-Informed Strategies in Development

Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…

Certara2026 年 4 月 22 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

生物制剂

A novel mathematical framework to predict in vivo bispecific GTX-B001 binding in skin, and translation to humans

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data

Expert Q&A: Identify Winning Biotherapeutics in Early Discovery

Integrated mechanistic modeling approaches in oncology drug development

将内源性配体竞争纳入治疗性单克隆抗体的机制全身 PBPK 模型

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

Applying AI-Driven Biosimulation to Drug Discovery

Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment

ADC Dose Optimization: Applying Model-Informed Strategies in Development

订阅时事通讯

快捷链接

解决方案

联系我们